Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Sectra buys Swedish imaging company RxEye
Sectra said it acquired RxEye AB and its cloud-based medical imaging platform for an undisclosed amount on Dec. 30, 2015.
The RxEye Cloud service is used to remotely view images by more than 2,000 users in European radiology, nuclear medicine and pathology departments and teleradiology services companies, Linköping, Sweden-based Sectra said. RxEye, which employs 6 workers, posted sales of about $833,000 last year (SEK 7 million), Sectra said. Read more
2. InVivo Therapeutics wins FDA approval for pivotal trial of spinal scaffold
InVivo Therapeutics said that it won FDA approval to shift a pilot trial of its spinal scaffold to a pivotal probable benefit study.
Cambridge, Mass.-based InVivo said it expects the FDA to OK its Inspire study, designed to enroll 20 patients with spinal cord injuries, after it submits 6-month data during the 2nd quarter from 5 patients already enrolled in the pilot study. Read more
1. Bosch gets in on $3m Series B for Emperra’s ‘smart’ diabetes system
Emperra said that it closed a Series B round worth $3.1 million for its Esysta “smart” diabetes management system.
Potsdam, Germany-based Emperra said the VC arm of the Bosch Group, Robert Bosch Venture Capital, joined existing backers Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Christian Krey and CTO Dr. Janko Schildt also got in on the round, Emperra said. Read more
